Henker J, Hoffmann D, Paul D, Hein J, Paditz E
Klinik für Kinderheilkunde, Medizinische Akademie, Dresden.
Fortschr Med. 1993 Feb 10;111(4):53-6.
In 30 children suffering from cystic fibrosis, the long-term effect (2 years) of treatment with an acid-protected micro-encapsulated pancreatin preparation was investigated in comparison with prior enzyme replacement with a conventional pancreatin preparation given over a period of years. Assessment criteria was the development of body length and body weight, lung function (vital capacity, FEF1) and the Shwachman-Kulczycki score.
The therapeutic efficacy of the acid-protected micro-encapsulated preparation is considered to be higher than that of conventional preparations, since the same effect was achieved with only one-quarter to one-third of the pancreatin dose of the conventional preparation (average: 6.5 +/- 2.9 g pancreatin/d, as compared with 1.6 +/- 0.6 g pancreatin in the case of the acid-protected micro-encapsulated preparation). However, none of the clinical parameters investigated revealed any significant changes during the course of the observation period. The results indicate that, if the general state of health and nutritional status of patients with cystic fibrosis is to be improved further, in addition to a special diet, attempts must be made to achieve further optimization of the intraluminal digestion.
在30名患有囊性纤维化的儿童中,对一种酸保护微囊化胰酶制剂的长期治疗效果(2年)进行了研究,并与数年来一直使用的传统胰酶制剂进行酶替代治疗的效果进行了比较。评估标准为身长、体重的增长情况、肺功能(肺活量、第1秒用力呼气量)以及施瓦克曼-库尔奇茨基评分。
酸保护微囊化制剂的治疗效果被认为高于传统制剂,因为达到相同效果时,酸保护微囊化制剂的胰酶剂量仅为传统制剂的四分之一到三分之一(平均:传统制剂为6.5±2.9克胰酶/天,酸保护微囊化制剂为1.6±0.6克胰酶)。然而,在观察期内,所研究的任何临床参数均未显示出任何显著变化。结果表明,如果要进一步改善囊性纤维化患者的总体健康状况和营养状况,除了特殊饮食外,还必须努力进一步优化肠内消化。